Literature DB >> 29344099

Audit of the management of patients at high risk of carbapenemase-producing enterobacteriaceae (CPE): Are we ready?

Lasantha Ratnayake1, Amy Harris1, Doreen Ko1, Linda Hawtin1.   

Abstract

BACKGROUND: Incidence of carbapenemase-producing enterobacteriaceae (CPE) in the UK is increasing. In 2013, Public Health England (PHE) published a toolkit to control spread of CPE within healthcare settings. AIM: To assess compliance to hospital CPE policy (adapted from PHE) in the identification, isolation and screening of suspected CPE patients.
METHODS: Admission booklets of 150 patients were evaluated to see whether the relevant section had been completed to identify high-risk CPE patients. Where necessary, patients were interviewed or their GPs were contacted to assess their CPE risk. Additionally, 28 patients screened for CPE were audited to assess compliance to screening and isolation.
FINDINGS: Only 23 patients out of 147 (15.6%) were risk assessed on admission. Risk status of 27 (18.4%) patients could not be assessed due to lack of data. Fifteen patients out of 28 (54%) screened for CPE were identified and isolated on admission. Ten out of 19 patients (53%) had three screens 48 h apart. DISCUSSION: This audit highlights difficulties in screening based on individual risk factors as the majority of patients were not screened on admission and documentation on isolation and screening was poor. More needs to be done to raise awareness of the requirements for routine assessment, isolation and screening.

Entities:  

Keywords:  Audit; carbapenemase; carbapenemase-producing enterobacteriaceae (CPE); enterobacteriaceae

Year:  2017        PMID: 29344099      PMCID: PMC5761931          DOI: 10.1177/1757177417705192

Source DB:  PubMed          Journal:  J Infect Prev        ISSN: 1757-1782


  5 in total

1.  Identifying Patients at High Risk for Carbapenem-Resistant Enterobacteriaceae at Admission: Nurse-Led or Doctor-Led?

Authors:  Gabrielle Chia; Jia Qi Kum; Kalisvar Marimuthu; Poh Bee Fong; Brenda Ang
Journal:  Infect Control Hosp Epidemiol       Date:  2015-12-22       Impact factor: 3.254

2.  Screening suspected cases for carbapenemase-producing Enterobacteriaceae, inclusion criteria and demand.

Authors:  Vella Venanzio; Myriam Gharbi; Luke S P Moore; Julie Robotham; Frances Davies; Eimear Brannigan; Tracey Galletly; Alison H Holmes
Journal:  J Infect       Date:  2015-06-10       Impact factor: 6.072

3.  Active case finding for carbapenemase-producing Enterobacteriaceae in a teaching hospital: prevalence and risk factors for colonization.

Authors:  K Poole; R George; V Decraene; K Shankar; J Cawthorne; N Savage; W Welfare; A Dodgson
Journal:  J Hosp Infect       Date:  2016-06-29       Impact factor: 3.926

4.  Universal hospital admission screening for carbapenemase-producing organisms in a low-prevalence setting.

Authors:  Jonathan A Otter; Eleonora Dyakova; Karen N Bisnauthsing; Antonio Querol-Rubiera; Amita Patel; Chioma Ahanonu; Olga Tosas Auguet; Jonathan D Edgeworth; Simon D Goldenberg
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

5.  KPC enzymes in the UK: an analysis of the first 160 cases outside the North-West region.

Authors:  Jacqueline Findlay; Katie L Hopkins; Michel Doumith; Danièle Meunier; Camilla Wiuff; Robert Hill; Rachel Pike; Richard Loy; Nazim Mustafa; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2016-02-03       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.